Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
HIL-214 by HilleVax for Gastroenteritis: Likelihood of Approval
HIL-214 is under clinical development by HilleVax and currently in Phase II for Gastroenteritis. According to GlobalData, Phase II drugs...
Data Insights
Risk adjusted net present value: What is the current valuation of HilleVax's HIL-214?
HIL-214 is a subunit vaccine commercialized by HilleVax, with a leading Phase II program in Gastroenteritis. According to Globaldata, it...